XERS
Xeris Biopharma Holdings, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Xeris Biopharma (XERS) Stock: Buy, Sell, or Hold?
$16.65
+0.13 (+0.79%)
▲
5d:
+27.29%
30d:
+70.42%
90d:
+93.6%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (14%)
Quality Score
38/100
Position
EXTENDED
30-Day Fair Range
$9.31 – $13.63
Position: EXTENDED
Forward P/E & Valuation
51.2x
STRETCHED
vs 22.3x historical avg
Wall Street Target
$17.29
+3.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$10.08 / $16.88
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: XERS is 22.2% above its trading range ($13.63). Market expects 32.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $16.65, which is considered extended relative to its 30-day fair value range of $9.31 to $13.63. From a valuation perspective, the stock is trading at a premium (Forward PE: 51.2) compared to its historical average (22.3). At these levels, the market is pricing in 32.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is in a uptrend. The price is approaching resistance at $16.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XERS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XERS is in a uptrend. The price is approaching resistance at $16.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XERS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.31 -
$13.63
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
14.3%
Trading Range & Key Levels
30-Day Trading Range
$9.31 -
$13.63
Current vs Trading Range
EXTENDED
Support Level
$10.08
Resistance Level
$16.88
Current Trend
Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price significantly overextended (+22.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.29)
- NEUTRAL: PE elevated vs history but 32.0% growth expectation is conservative given 1616% recent growth
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
51.23
Wall Street Target
$17.29
(+3.8%)
Revenue Growth (YoY)
44.2%
Earnings Growth (YoY)
1616.2%
Profit Margin
-1.8%
Valuation Premium vs History
+32.0% premium
PE vs Historical
51.2 vs 22.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+32.0%
(market-implied from PE analysis)
1-Year Target
$21.98
(+32%)
2-Year Target
$29.01
(+74%)
3-Year Target
$38.29
(+130%)
3-Yr Target (if PE normalizes)
(PE: 51→22)
PE COMPRESSION
$16.67
(+0%)
Earnings growth offset by PE compression
Share XERS Analysis
Share this live XERS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (XERS)
Bullish
4 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
3 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
Apple, Xeris Biopharma Holdings, and Zeta Global Holdings reached 52-week highs on Wednesday due to strong financial results and Wall Street price target updates.
Key Retail Themes:
Financial Results
Price Target Updates
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 60 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive XERS Research Pages